[177Lu]Lu-DOTA-TATE as First-line Therapy for Patients With Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): The NETTER-2 Study

被引：0

作者：

Singh, Simron ^{[1
]}

Pavel, Marianne ^{[2
]}

Kunz, Pamela L. ^{[3
]}

de Herder, Wouter ^{[4
]}

Herrmann, Ken ^{[5
]}

D'Amelio, Anthony M., Jr. ^{[6
]}

Santoro, Paola ^{[6
]}

Folitar, Ilya ^{[7
]}

Ferone, Diego ^{[8
,9
]}

机构：

[1] Univ Toronto, Toronto, ON, Canada

[2] FAU Erlangen Nurnberg, Erlangen, Germany

[3] Yale Univ, Yale Sch Med, New Haven, CT USA

[4] Erasmus MC, Rotterdam, Netherlands

[5] Univ Klinikum Essen, Essen, Germany

[6] Novartis Pharmaceut, E Hanover, NJ USA

[7] Adv Accelerator Applicat, Geneva, Switzerland

[8] IRCCS Policlin San Martino, Endocrinol, Genoa, Italy

[9] Univ Genoa, DiMI, Genoa, Italy

来源：

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

T-3

引用

页码：E58 / E58

页数：1